The European Medicinal Agency has examined the new information available on cases of lung cancer detected in patients in exubera treatment and has determined that these cases are included in drug prescriptions.
Specifically, the cases of lung cancer are seven: six former patients and volunteers during clinical studies prior to the commercialization of exubera, and one that has used exuberate once the product is marketed.
The "company" has decided, now, which she, who will continue studying, in the next two years, to the patients who have used exubera
Despite the controls and the time required by the market of a new medicine, there is always the risk of being the first in ..., and not only in this area there are risks, think but about the mobile telephony boom, do we know exactly how the waves they generate are really innocuous?... is the usual, learn based on trial and error ... pity that in the case of health, you play with lives of people ... :(
De los buenos tiempos, siempre quiero más... Mamá de Ángela, ¡16 añitos, fiera!. Debut: octubre de 2003. Bomba insulina Medtronic Paradigm Veo desde junio 2005 Última hemo 6.1
In this precise case it is about "time" and here it has not been respected;They have tried to sell on a large scale (Spain and Brazil and about the behavior of these two governments there would be much to discuss) from the beginning a "product" knowing that it was totally inappropriate as it was then and if they have retired, let's not fool ourselves, it has not surely been due to economic problems or at least not those they have alleged.What is true that they will have studied, but not the investigators but the lawyers are the possible economic losses caused by other "losses" if the story became public and clear as things were, the accounts did not square.
Anyway, this shows that there is nothing better than a good ruthless competition and a good correveydile system, so that the rules are respected, the good ... less gives a stone: ((((((
